share_log

康诺亚-B(02162.HK):CM336 I/II期临床研究最新数据在第66届美国血液学会(ASH)年会上以壁报形式公布

Kangnuo Ya-B (02162.HK): The latest data from the CM336 Phase I/II clinical research was presented in poster form at the 66th Annual Meeting of the American Society of Hematology (ASH).

Gelonghui Finance ·  Dec 9, 2024 00:32

On December 9th, Gelonghui reported that KANNUA-B (02162.HK) announced its latest data from the phase I/II clinical study of the BCMAxCD3 bispecific antibody CM336 for the treatment of relapsed or refractory multiple myeloma, which was presented in poster form at the 66th American Society of Hematology (ASH) annual meeting.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment